Downstream KRAS mutations are particularly known to develop drug resistance, leading to the recommendation that anti-EGFR antibodies (i.e., cetuximab) in conjunction with chemotherapy be used only for metastatic CRC patients with RAS-wild type.48 This evidence concerns the gene KRAS and colorectal carcinoma.